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1. Introduction
It is undisputable that a multifaceted biological interplay exists between the skin and the liver.
The integument can firstly be viewed as a ‘gate’ through which hepatotropic viruses may
access the blood stream. In this respect, one may think of the huge number of B and C virus
hepatites that must have been acquired in a more or less distant past due to either intravenous
drug consumption, use of contaminated equipment in beauty and health care-related proce‐
dures, or even dermal tattooing. Moreover, one may consider that some cases of herpes simplex
virus hepatitis have been reported in the literature which are not unlikely ascribable to systemic
dissemination from primary muco-cutaneous lesional foci.
Yet, the skin may also be viewed as a ‘mirror’ capable of projecting on the body surface more
or less specific echoes of disease conditions involving the liver. A recent review of the issue by
Hazin and coworkers [1] is introduced by the following simple but just as brilliant statement:
“Dysfunction in the body’s second largest organ, the liver, often yields changes in the body’s
largest organ, the skin”. The most trivial paradigm sustaining such an obvious assumption is
jaundice when it is sustained by primary failure of hepatocytes to perform one of their main
functions, that is to conjugate bilirubin into a secretable form. However, further and less
obvious paradigms, such as cutaneous manifestations of mixed cryoglobulinemia in HCV
infected patients, will also be discussed.
Since the issue that will be specifically reviewed in this chapter is all the many possible links
between skin and virus-induced liver disease, this introductory framework is to be completed
by mentioning the not unusual circumstances in which neither the skin nor the liver disease
in itself, but treatments undertaken to cure a disease of one of the two organs may have
undesired consequences on the other one. This seems obviously true thinking of some double-
edged risky circumstances in which either worsening of psoriasis in patients undergoing
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interferon plus ribavirin therapy, or reactivation of latent viral infections under immunosup‐
pressive treatment of the skin disease, is observed.
2. The skin as a ‘gate’ for hepatotropic virus infections
2.1. Tatooing as risk factor for viral liver disease
Tatooing has been practiced for many centuries worldwide, and is a well-established risk factor
for transfusion-transmitted diseases, including HBV and HCV [2]. A recent meta-analysis
highlights that the above menace is still currently far from being remote, especially in certain
at-risk categories (such as prison inmates and subjects undergoing home-made procedures
without proper aseptic techniques) [3].
2.2. Rare forms of viral hepatitis caused by agents which usually involve only the skin
After primary infection, in the absence of any severe immune deficiency condition, herpesvi‐
ruses like Herpes Simplex Viruses (HSV) type 1 or 2, and Varicella-Zoster virus (VZV) establish
latency by remaining dormant in the dorsal root nerve ganglia. Viral reactivation results in
cutaneous or muco-cutaneous manifestations that usually run an overall benign course (Figg
1, 2, 3), with an inflamed vesicular and/or bullous rash which is customarily restricted to a
limited district of the body surface. Though in some patients rather impressive clinical scenarios
may be observed (Figg. 4, 5 and 6), herpetic lesions tend to heal within few weeks, with no or
only minor scarring and dyschromic sequelae. As for VZV, post-herpetic neuralgia develops
quite rarely, and is the worst occurrence reported after skin manifestations have faded.
In otherwise healthy subjects, disseminated herpes simplex virus hepatitis have been reported
very exceptionally. In one case described by Miyazaki and coworkers in 1991 [4], the possibility
that patient’s mucosal herpetic lesions might have behaved as a ‘gate’ for a large virus inoculum
leading to visceral involvement either directly or after having overwhelmed local immune
defenses has been considered.
By contrast, HSV and VZV hepatitis are possible in patients whose cell-mediated immunity is
severely impaired, for instance in malignancy or organ transplanted patients [5]. In these cases,
the skin rash may either be absent, coincide with, or supervene after visceral involvement.
When cutaneous lesions are present, severity of skin involvement is often significantly
increased compared to standard clinical pictures both in terms of number of lesions, diffusion
over the body surface, and severity of tissue impairment. Notably, in a recent review of 74
cases of herpes simplex hepatitis [6], Sharma and Mosunjac highlighted that proper diagnosis
was delayed in more than two-third of cases, despite a herpetic muco-cutaneous involvement
was present in at least 70% of patients. Conversely, the occurrence of an unexplained impair‐
ment of liver function tests in an immunocompromised patient exhibiting skin herpetic lesions
should always arouse a high degree of suspicion of visceral dissemination [7]. Fulminating
herpetic hepatitis is a life-threatening occurrence, but it can be treated effectively if therapy is
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started early. Inclusion of herpes virus in the differential diagnosis procedures is thus man‐
datory.
Figure 1. Herpes simplex labialis
Figure 2. Herpes simplex on the foot: an unusual localization
Figure 3. Herpes simplex progenitalis
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Figure 4. Severe herpetic gingivostomatitis
Figure 5. Severe cutaneous herpes simplex with extensive vesico-bullous elements
Figure 6. Severe, necrotic and hemorrhagic herpes zoster
3. Skin manifestations occurring in viral liver disease
3.1. Skin manifestations related to HCV
Cutaneous manifestations of acute infection are sporadic and show no substantial specificity,
ranging from urticaria, erythema multiforme, leukocytoclastic vasculitis to erythema nodo‐
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sum. On the contrary, there exists a wide panel of skin conditions linked, to a varying degree,
with chronic HCV infection [8, 9]. The occurrence of skin disorders of any type has been in fact
reported in up to 17% of HCV patients (Table 1) [10]. In this context, the association with the
‘big three’ i.e. mixed cryoglobulinemic vasculitis, porphyria cutanea tarda and lichen planus
show the highest robustness on both biological and epidemiological ground. On the other
hand, the clinical alliance between HCV and a broad list of other skin conditions has not yet
received sufficient support [9, 11]. In this context, anecdotal reports have mostly been made
in the literature of associations with pityriasis rubra pilaris [12], sarcoidosis [13], vitiligo [8],
cholestatic and non-cholestatic pruritus [14, 15], prurigo nodularis [16], cutaneous polyarteritis
nodosa [17], pyoderma gangrenosum [18], subacute cutaneous lupus erythematosus [19],
primary localized cutaneous amyloidosis [20], pigmented purpuric dermatosis [21], actinic
porokeratosis [22], pityriasis lichenoide [23], generalized granuloma annulare [24], dissemi‐
nated Kaposi’s sarcoma [25] and necrolytic acral erythema [26]. Of note, in most of the above
circumstances it seems quite difficult to sift consistently the direct contribution of HCV
infection per se from that attributable to antiviral treatment. A data set which is therefore of
the outmost relevance in this regard is that provided by an U.S. nationwide hospital-based
case-control study in which El-Serag and coworkers [8] surveyed comorbidity in as many as
34,204 HCV-infected subjects, the vast majority of whom (notably, >95%) were naïve to
antiviral therapy. In this study, the aforementioned strong association with cryoglobulinemia,
porphyria cutanea tarda and lichen planus found an authoritative confirmation. However, a
statistically significant link was also observed with vitiligo, but this finding did not receive
further comparable support from the rest of the literature, and remains rather inexplicable.
3.1.1. Mixed cryoglobulinemic vasculitis
Cryoglobulins are a family of anomalous proteins which tend to precipitate at low tempera‐
tures (<37°C), such as those currently found in the extremities (namely hands, feet, ear and
nose). The prototype of cryoglobulinaemic diseases in HCV infected patients is ‘mixed
cryoglobulinemia’ (MC). Of note, up to more than a half of HCV-infected patients show
circulating cryoglobulins, and rates of 30 to 100% of HCV positive serologies have been
reported in carriers of circulating cryoglobulins, with an unexplained predominance in the
Mediterranean basin.
In MC tissue damage results from deposition of immune complexes containing rheumatoid
factor, polyclonal IgG, complement and HCV RNA on endothelial surfaces of small- to
medium-sized vessels, which in turn leads to vascular inflammation. The prevalent histolog‐
ical pattern of MC is neutrophilic ‘leukocytoclastic’ vasculitis; however, ‘necrotizing’ vasculi‐
tis, with intimal fibrinoid necrosis and infiltration of the entire vessel wall and perivascular
space, may also be observed [27].
The skin is one of the most commonly affected organs, along with kidneys and peripheral
nerves. Thus, the dermatologist may play a helpful role in early detection of previously
unrecognized HCV infections. In fact, the appearance of cutaneous lesions on extremities,
particularly in cooler weather, must always raise clinical suspicion. The spectrum of skin
involvement in MC ranges widely from ‘palpable purpura’ (which is the absolutely prevalent
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clinical scenario) [9] to urticarial vasculitis, necrotizing vasculitis, isolated necrotic ulcers, acral
ischemias, acrocyanosis, and livedo reticularis (Figure 7 and 8). Of note, even in cases charac‐
terized by the highest clinical severity, the skin behaves very often like a sort of ‘emuntory
system’, with poor or absent signs of internal organ involvement. Systemic vasculitis, involv‐
ing the kidneys, the heart, the central nervous system and other viscera, is in fact unusual.
First-line treatment of MC diseases consists of associated pegylated INF-α and ribavirin. In
patients who are intolerant to antivirals, or those with severe systemic disease, or those who
have failed to reach SVR after antiviral therapy, symptomatic treatment with plasmapheresis,
steroids or rituximab should be considered [27].
3.1.2. Porphyria cutanea tarda
Porphyria cutanea tarda (PCT) is related to a deficient activity of the heme synthetic enzyme
uroporphyrinogen decarboxylase (UROD), which may in turn be sustained by either UROD
gene mutations or acquired liver insufficiency [28]. A strong association has been reported
between acquired PCT and HCV infection. HCV prevalence in PCT sufferers is significantly
Disorders with an obvious linkage with HCV
-mixed cryoglobulinemic vasculitis
-porphyria cutanea tarda
-lichen planus
Other skin diseases described in association with HCV
-pityriasis rubra pilaris
-sarcoidosis
-vitiligo
-cholestatic and non-cholestatic pruritus
-prurigo nodularis
-cutaneous polyarteritis nodosa
-pyoderma gangrenosum
-subacute cuteneous lupus erythematosus
-primary localized cutaneous amyloidosis
-pigmented purpuric dermatosis
-actinic porokeratosis
-pityriasis lichenoide
-generalized granuloma annulare
-disseminated Kaposi’s sarcoma
-necrolytic acral erythema
Table 1. Skin manifestations in hepatitis C infection
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higher than that reported in the general population. Prevalence rates range from 17 to 65%,
the latter having been reported in Southern Europe [29, 30]. However, HCV alone is not likely
to cause the disease, but it is thought to be a strong trigger for the development of deranged
porphyrin metabolism in subjects with other known predisposing factors (such as, alcohol
abuse or iron overload) [31].
Laboratory diagnosis is based on detection of increased levels of uro-carboxyl porphyrins and
heptacarboxyporphyrins in the urine, and on the presence of isocoproporphyrin in the feces.
Due to its porphyrin content, the urine of PCT patients is discoloured (chiefly after air and
light exposure), while all ‘iron tests’ are negative. On clinical ground, diagnosis derives from
an array of dermatological findings, as follows: vesicular or vesico-bullous swellings on skin
sites subjected to even minor actinic and/or mechanic traumas; ensuing eroded areas that take
weeks or months to heal; scarred and/or melasma-like hyperpigmented patches; keratin-filled
milial cysts; lilac erythematous rash of periorbital areas; hypertrichosis on the lateral aspects
of the face; chloracne; skin dystrophic calcifications with ulceration; alopecia; and onycholysis.
3.1.3. Lichen planus
Lichen planus (LP) [32] is an inflammatory immune mediated disease of the skin and/or
mucous membranes most commonly affecting middle-aged adults of both sexes, the etiology
of which has not yet been fully clarified. The occurrence of the disease in the general population
is rare. Prevalence rates of 0.1 to 0.3 have been calculated for cutaneous LP, and of 1.15 to 2.3
for mucous (oral) LP. However, the persisting lack of aim-oriented studies based on standar‐
dized methods and criteria results in some uncertainty [33].
Clinically, cutaneous LP is characterized by flat, polygonal, lilac red papules which may
remain isolated, or merge into larger plaques (Figure 9 and 10). The rash has an unpredictable
duration, from few weeks to several months or years. Lesions may resolve with atrophy,
scarring or brownish hyperpigmentation. The flexor aspects of the limbs, the upper back, and
the lumbar region are frequently involved, but the disease can spread over the entire body
surface. Hair and nails may also be affected. Severe, recalcitrant itch is very common. Mucous
LP chiefly affects the mouth and, less frequently, genitalia, conjunctiva, and esophagus. The
mucosal lesions consist of erosive erythematous patches (Figure 11), or horny micro-papules
arranged in a reticular pattern recalling a lace network (or a sprinkle of lime) (Figures 12 and
13), or a combination of both (Figure 14). The erosive variant is usually accompanied by intense
burning sensations.
LP histology is the prototype of a morphological scenario that has traditionally been referred
to as “lichenoid tissue reaction/interface dermatitis”, in which a band-like mononuclear cell
inflammatory infiltrate in the papillary dermis obscuring the dermal-epidermal junction (DEJ)
is seen, coupled with more or less pronounced epithelial changes, as follows: hydropic/
vacuolar degeneration in the basal cell layer, scanty ‘ghost’ epithelial cells (‘colloid bodies’),
spongiosis and clefting at the DEJ (‘Max Joseph spaces’), irregular acanthosis and thickening of
the granular layer, dense hyperkeratosis, disappearance of intra-epidermal melanocytes along
with melanin ‘leakage’ into the dermis (pigmentary incontinence) (Figure 15).
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The pathogenesis of LP has not yet been fully elucidated, however the disease is universally
alleged to be an autoimmune disease. The prominence of certain HLA haplotypes (such as,
HLA-DR1), or detection of cytokine gene polymorphisms in some case series [34], support a
genetic predisposition to the disease. The basal epidermis injury observed in LP is attributed
to cytotoxic T lymphocytes, which in fact predominate into the infiltrate along with minor
subpopulations of macrophages and dendritic cells. In this context, a significant role of
plasmacytoid dendritic cells has been also recognized. In fact, these cellular effectors are
viewed as the driving force to the end-stage T cell-mediated epidermal damage, in that they
would be able to give rise to an inflammatory type I interferon signaling pathway which, in
turn, would amplify and maintain cytotoxic T cell attack to keratinocytes [35]. Cross-reactivity
between endogenous and environmental antigens is widely suspected, but the exact nature of
the triggering antigen is still obscure. Among the putative exogenous factors involved in LP,
one of the most outstanding candidates appears to be HCV. An ample body of biological
evidences supporting this view exists in the literature, and has been reviewed in recent years
[36, 37]. However, the conclusive proof of the causal linkage between HCV and LP is still
lacking. These circumstances have recently led Baccaglini and coworkers [37] to launch
somewhat provocatively the subversive hypothesis of a fake association via a ‘third factor’
consisting of a still unidentified confounder.
However, at least on epidemiological grounds, the existence of a ‘two-way’ association
between LP and HCV infection seems currently beyond question worldwide. On these regard,
two well-designed meta-analyses have been recently carried out showing that LP sufferers
have an odds ratio of being HCV seropositive up to 5.4 times higher compared to controls, and
that the risk of having LP is up to 4.47 times higher in HCV patients than in seronegative
controls [38, 39]. On the basis of these circumstances, screening for anti-HCV antibodies is
substantially advisable in patients with LP, especially in countries with the highest seropre‐
valence rates. In this regard, it has been suggested that routine HCV testing would be cost-
effective in geographical districts in which HCV prevalence is 7% or more [40]. Yet, in the
absence of standardized criteria and guidelines, individual case-by-case screening strategies
are more suitably recommended [37].
This section is to be concluded by underscoring that true cases of idiopathic LP need sometimes
to be differentiated from so-called lichenoid eruptions (LE), which somehow resemble LP on
both clinical and histological grounds [41]. LE are often caused by (and develop at sites of)
contact with dental restorative amalgams or stomatological devices, due to their content of
methacrylic acid esthers, nickel, mercury, copper and gold [32]. However, LE may be also
induced by a huge array of systemic drugs whose number is in steady increase [42], ranging
from angiotensin-converting enzyme inhibitors to non-steroidal anti-inflammatory drugs,
antimalarials and proton pump inhibitors. The reader should be aware that the list includes
the agents employed for treatment HCV infection, interferon and ribavirin [43]. In such
occurrences, LE may either be exanthematic, or stay confined to oral mucosa, or just involve
the site of interferon injection [43].
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3.2. Skin manifestations related To HBV
Both range and frequency of extrahepatic manifestations in patients with HBV infection are
considerably lower compared with those observed in HCV infected subjects [44, 45]. A French
multicenter, retrospective, cross-sectional study of 190 patients with chronic hepatitis B has
rated the overall incidence of clinical and biologic extrahepatic manifestations to be 16% and
15%, respectively [46]. As more specifically regards the skin, vasculitis, psoriasis and pruritus
were found to occur in only 1% of cases each. Of note, in striking contrast with HCV popula‐
tions, in HBV patients cryoglobulinemia and related disease manifestations have been
reported in only 2% of cases. Many clinical and laboratory observations have long cast
significant doubts on the actual biological relevance of this association. On this regard,
literature yields rates up to 15% for cryoglobulin detection in HBV patients, although no signs
or symptoms of related vasculitis are observed in the great majority of cases [47].
Both cutaneous and non-cutaneous extrahepatic manifestations of HBV infection have been
largely attributed to deposition of circulating immune complexes (IC) containing HBs and/or
possibly HBe antigens. Alternatively, induction of local IC formation by viral antigens,
interaction between tissue antigens and virus-induced autoantibodies, or direct tissue damage
by viral replication have also been invoked. However, this issue remains highly controversial
[45, 48, 49].
Cutaneous manifestations of HBV infection (Table 2) are observed both in the incubation,
prodromal phase and in chronic state of disease. In the former, a clinical scenario in which
intermingled signs of either a mild ‘flu-like’ or a more serious ‘serum sickness-like’ syndrome
have been described. In this phase, up to 30% of the patients may have fever, weakness,
headaches, arthralgias/myalgias, and glomerulonephritis which not infrequently develop in
association with varied dermatological manifestations, such as non-specific (toxic) erythema,
urticaria, angio-oedema, erythema multiforme, erythema nodosom, Henoch-Schonlein
(rheumatoid) purpura, or palpable purpura [44, 45, 50-53]. Other extrahepatic manifestations
of HBV infection in which skin involvement is either a prominent feature or an ancillary finding
include Gianotti-Crosti syndrome and polyarteritis nodosa, respectively.
3.2.1. Gianotti-crosti syndrome
Gianotti-Crosti syndrome (GCS) [54], also termed ‘papular acrodermatitis of childhood’, is a
peculiar, self-limited and largely asymptomatic skin eruption featuring almost monomor‐
phous papular or papulovesicular lesions located mainly on the face and distal aspects of the
four limbs (Figure 16). Mucosal involvement is never described. Histology is noncontributory,
with upper dermis perivascular round cellular infiltrates and endothelial swelling as the
prevailing findings. Children aged from a few months to 15 years (with a peak between 1 and
6 years) are mostly involved, but adults (of note, only females) may be also affected. Sponta‐
neous recovery usually occurs within 25 to 45 days. Systemic findings, which are observed
rarely, include malaise, fever or diarrhea. Limited lymphadenopathy, splenomegaly and
hepatomegaly are sometimes detected. When present, hepatitis is usually anicteric. Originally
described as in strict conjunction with sole HBV infection, GCS has been subsequently linked
to an array of infectious agents, including other viruses (such as, HAV, CMV and EBV) and
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bacteria (such as, Borrelia burgdorferi and β-hemolytic streptococci). Neither viral bodies nor
viral antigens have ever been demonstrated in the context of skin lesions, and the pathogenesis
of GCS remains largely unclear. Current views on the issue span from a role of immune
complex deposition to occurrence of virus-related delayed hypersensitivity reactions. Fur‐
thermore, an association between immunization and GCS has long been outlined, with anti-
HBV and anti-HAV vaccinations being included in the list of triggering factors [54-57].
Remarkably, it has been proposed that occurrence of GCS after the first vaccine administration
does not contraindicate completion of the immunization protocol, as GCS does not recur after
the subsequent boostering injections [55]. Finally, in addition to that with GCS, an association
has also been reported between HBV infection and a much rarer, but equally peculiar skin
eruption involving the extremities, i.e. so-called ‘papular-purpuric gloves and socks syn‐
drome’, in which a triggering role of HBV (along with other infections such as measles,
parvovirus B19, coxsakie B6 and cytomegalovirus) has been assumed [58].
3.2.2. Polyarteritis nodosa
Recognition of a strong linkage between HBV and polyarteritis nodosa (PAN) dates back to
the 1970s. Rates of prevalence of positive HBV serologies have been estimated up to 50% among
PAN patients. However, these figures have decreased significantly over the last four decades,
and are currently less than 5% [45]. A major role in this respect must have been played by
improved blood transfusion safety measures, other general hygiene precautions and extensive
vaccination campaigns. The pathogenesis has largely been attributed to deposition of immune
complexes containing HBsAg. Of note, unlike other forms of PAN, in HBV-related PAN serum
antineutrophilic cytoplasmic antibodies (ANCA) are only exceptionally detected. Histologi‐
cally, PAN is characterized by transmural, usually segmental, necrotizing infiltration of
medium-to-small vessels resulting in ischaemia, infarcts and haemorrhage, which ultimately
lead to end-organ damage. If untreated, the course of PAN is often protracted, and symptoms
and signs of multi-organ involvement are generally observed. Organs more commonly
affected are kidneys, heart, gut and peripheral nerves. Cutaneous PAN has also been reported
in 10 to 50% of cases, depending on the case series examined. Livedo reticularis and painful
subcutaneous nodules (usually along the arteries of the lower limbs) are commonly described.
Nodules ulceration and distal gangrene are frequent findings as well [44, 59, 60].
Further anecdotal reports of skin disorders observed in conjunction with HBV infection
include acanthosis nigricans [61] and generalized granuloma annulare [62]. Finally, the
association with lichen planus (LP), which is now undisputed in HCV infection, is instead
highly controversial in HBV carriers. A number of earlier studies have provided some support
for this view, but such biological alliance has more recently received repeated confutations [63,
64] and is currently considered unfounded.
3.2.3. Skin unfavorable effects of HBV immunization
Hepatitis B vaccination may also be hazardous for the skin. In this respect, the following
dermatological undesired manifestations have been reported: erythema nodosum [65],
generalized granuloma annulare [66], Gianotti-Crosti syndrome [54, 56, 67], cutaneous
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polyarteritis nodosa [68] and pityriasis rosea-like rash [68], lichen planus [69], lichenoid and
pseudolymphomatous reactions confined to site of injection [70], and generalized pseudo‐
lymphomatous reactions [71].
3.3. Skin manifestations related to HAV
Apart from the ‘paradigm’ of jaundice, HAV infection is very occasionally linked to significant
cutaneous side-events. Few reports have been made of urticaria, purpura or other exanthemas
[72]. A case of Henoch-Schönlein purpura has been described after immunization [73].
Figure 7. Palpable purpura
-urticaria
-angio-oedema
-non-specific (toxic) erythema
-erythema multiforme commonly observed in the prodromal phase of infection
-erythema nodosom
-Henoch-Schonlein purpura
-palpable purpura
-Gianotti-Crosti syndrome (‘papular acrodermatitis of childhood’)
-polyarteritis nodosa
-acanthosis nigricans
-generalized granuloma annulare
-lichen planus (highly controversial)
Table 2. Skin manifestations in hepatitis B infection
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Figure 8. Nodular, necrotic vasculitis
Figure 9. Cutaneous lichen planus (LP): flat, polygonal, lilac red-coloured pruritic papules (Courtesy of Professor M.
Lomuto, Bari, Italy)
Figure 10. Cutaneous LP (Courtesy of Professor A. J. Kanwar, Chandigarh, India)
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Figure 11. Mucous LP: erosive variant (Courtesy of Professor M. Lomuto, Bari, Italy)
Figure 12. Mucous LP: papular, hyperkeratotic variant (‘lace network’ pattern) (Courtesy of Professor M. Lo Muzio,
Foggia, Italy)
Figure 13. Mucous LP: papular, hyperkeratotic variant (‘sprinkle of lime’ pattern) (Courtesy of Professor E. Bonifazi,
Bari, Italy)
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Figure 14. Mucous LP: mixed type, with a combination of erosive and hyperkeratotic lesions (Courtesy of Professor M.
Lo Muzio, Foggia, Italy)
Figure 15. Histological picture of LP: a fully developed prototype of so-called “lichenoid tissue reaction/interface der‐
matitis” (Courtesy of Professor P. Bufo, Foggia, Italy)
Figure 16. Gianotti-Crosti syndrome (‘papular acrodermatitis of childhood’) (Courtesy of Professor E. Bonifazi, Bari, Italy)
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4. Skin manifestations associated with treatment of viral liver disease
4.1. Skin adverse effects related to ‘standard of care’ treatment of chronic HCV infection
The ‘fingerprint detector’ effect
The combination of pegylated interferon α (PEG-INF) and ribavirin (RBV), which is the current
‘standard of care’ (SOC) in the management of chronic HCV infection, has significantly
improved the treatment outcome. Due to the side effect profile of both drugs, a considerable
number of chronic hepatitis C patients are ineligible for PEG-INF/RBV-based treatment
because of medical contraindications. Moreover, vast rates of patients are unable to tolerate
antiviral therapy, and account for nearly 10% of premature treatment discontinuations [74, 75].
More specifically regarding skin adverse events (AEs), in a recent large-scale prospective study
of 2871 Japanese patients, dermatologic undesired manifestations were the third most common
reason for therapy withdrawal [75]. INF alone may give raise to a wide variety of cutaneous
AEs, the frequency of which has been estimated from 13 to 23%, and the association with RBV
has led to an increased incidence of skin AEs compared to those observed during INF mono‐
therapy era [75-80]. Cutaneous AEs related to SOC treatment may be divided into three major
groups: local reactions occurring at INF injection sites (Figure 17); non-local or generalized
reactions; and signs of hypothyroidism caused by INF-induced autoimmune thyroiditis (Table
3). Local reactions are more consistently ascribable to the action of INF alone. By contrast, not
local or generalized manifestations have to be linked to both agents, considering that the modes
of action of INF and RBV are rather intermingled and their individual contribution seem thus
quite undistinguishable. As shown in the table, a long array of cutaneous manifestations have
been observed. Some reports are almost anecdotal, while the triad pruritus, skin xerosis and
eczematous lesions are the principal hallmark of ‘hepatitis C treatment-associated dermatitis’
according to an in-depth review recently carried out by Lübbe and coworkers [81]. Xerosis is
customarily spread over the entire body surface. Pruritus is also generalized, and is not rarely
refractory to standard antihistamine agents. Eczema, which mainly affects the extensor aspects
of limbs and sites exposed to friction (Figure 18 and 19), has been reported to sometimes take
the appearance of so-called ‘nummular’ (discoid) eczema (Figure 20 and 21 or prurigo
nodularis (Figure 22).
As regards ‘eczema’, an extensive discussion of the vast archipelago of disease conditions which
are currently collected under such term in the dermatological literature [82] is beyond the scope
of the present textbook. However, a brief digression on the matter will perhaps be useful to the
reader. Clinically, along with variable degrees of itching and soreness, eczematous dermato‐
ses display a variety of signs which range from acute to chronic forms as follow: erythema,
vesiculation, exudation, excoriation, fissuring, dryness, scaling, hyperkeratosis, papulation and
lichenification (Figure 23.A to -C). Accordingly, histological hallmarks vary from epidermal
oedema (‘spongiosis’), thickening of spinous and horny layers (‘acanthosis’ and ‘hyperkerato‐
sis’, respectively) and more or less dense round cell infiltrates in the dermis. The simplest
classification framework of  eczemas implies division into two forms,  i.e.  exogenous and
endogenous. Exogenous forms (also referred to as ‘contact dermatitis’) result from direct
exposure of the skin surface to toxic agents (‘irritant contact dermatitis’) or allergens (‘allergic
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contact dermatitis’). Cell-mediated (not humoral), ‘delayed’-type hypersensitivity is involved
in the latter. As a counterpart, in the endogenous forms all the other forms of eczema (rang‐
ing from atopic eczema to so-called discoid or nummular eczema) which are not attributable to
any recognizable contact offender, and whose pathomechanisms still remain largely obscure
are to be included.
Interferon-related injection site (local) reactions
-ill-defined, roundish, pruritic, self-recovering erythematous patches (Figure 17)
-vesico-bullous rashes
-Skin necrosis
-Dermal mucinosis
-Sarcoidosis
-Foreign body granulomatous reaction
-Lichen planus
-Patchy hypermelanosis
-Vasculitis
-Vitiligo
-Alopecia
Non local, or generalized reactions
-Generalized pruritus
-Skin xerosis
-Eczema
-Generalized nummular eczema
-Prurigo-like eruptions
-Meyerson’s phenomenon (‘halo dermatitis’) around melanocytic naevi
-Fixed drug eruption
-Nonspecific erythematous or maculopapular exanthemas
-Nonspecific ‘acantholytic dermatitis’
-Grover’s disease
-Dry pulpitis and fissured fingers
-Vitiligo
-Sarcoidosis
-Tongue hyperpigmentation
-Psoriasiform drug eruptions
-Psoriasis (triggered or worsened)
-Lichen planus (triggered or worsened) and other lichenoid eruptions
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-Cryoglobulinemic vasculitis (worsened)
-Leukocytoclastic vasculitis
-Pyoderma gangrenosum
-Polyarteritis nodosa
-Dermatitis herpetiformis and/or other gluten hypersensitivity states
-Rosacea fulminans
-Systemic lupus erythematosus
-Systemic sclerosis
-Alopecia areata and universalis
-Dystrophic alopecia and diffuse thinning of the hair
-Diffuse or localized hypertrichosis
-Hair curling
-Hair repigmentation
-Eyebrow and eyelash
Skin and hair signs of hypothyroidism caused by INF-induced autoimmune thyroiditis
-diffuse skin hyperkeratotic thickening
-scalp and body hair dryness and coarseness
-diffuse loss of scalp hair
-slow growth, dystrophy and atrophy of nails
-skin pallor
-carotenemia with skin yellowing (more prominently, on the palms, soles, and in the nasolabial folds)
-impaired wound healing
-petechial purpuric patches
References cited in this table are partly compiled from the works of Cacoub and coworkers [78], Mistry and coworkers
[77], Lübbe and coworkers [81], and Jadali [89].
Table 3. Cutaneous adverse events reported under INF plus RBV treatment of patients with chronic HCV infection
The ‘fingerprint detector’ effect - According to what has been said above, eczematous manifes‐
tations occurring during treatment for HCV infection may be classified as ‘endogenous’. This
seems appropriate also considering that no data are currently available in the literature
concerning possible past history of delayed-type hypersensitivity conditions or present skin
reactivity to standard contact allergen series in patients developing eczema under treatment
for HCV infection. In this context, it might be hypothesized that the combination of INF and
RBV acts as a sort of ‘fingerprint detector’ over the skin surface being able to unmask and
trigger reactivation of clones of skin-resident T cells that could have been primed at any time
in the past via indeterminable antigenic challenges, without ever exceeding the threshold
which could have given rise to overt clinical manifestations. Indeed, the skin is the outermost
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barrier against a huge number of environmental threats, including chemical and infectious
agents. So that the magnitude of immune host defense reactions taking place at any moment
in the skin are immeasurable. Since its first description by Streiler in 1989 [83], the so-called
‘skin-associated lymphoid tissue’ has acquired an ever-increasing number of immunological
prerogatives, including the capacity of keratinocytes (an ectodermal cell lineage), in concert
with Langerhans cells and dermal dendritic cells, to play a role in antigen-presenting processes
and, additionally, to prime naïve skin-reactive T cells directly [84]. Thus, some evidence has
been provided to look at the skin as a true lymphoid organ in its ability to mount an immune
response framework within its own milieu. Yet, there is still insufficient information on
biological mechanisms driving leukocyte migration and homing to target tissues in immune
responses and inflammation [85]. However, the hypothesis that memory CD8 T cells are able
to persist as a stable, ‘dormant’ population in the skin after specific priming has taken place,
has received authoritative confirmations from studies performed on both lichen planus (Figure
9 to 14) [86] and fixed drug eruption (Figure 24) [87], two prototypes of a vast group of skin
conditions (comprehensively referred to as ‘lichenoid tissue reaction/interface dermatitis’) in
which a common role of antigen presenting cell-mediated type I intereferon signaling has been
assumed [35]. Taken as a whole, all these data might provide the key to at least theoretically
closing the pathogenetic loop linking treatment and occurrence of the otherwise clinically ‘no
sense’ eczematous rashes in patients with HCV infection. However, a body of evidence which
is strict enough to fully clarify the exact mechanisms underlying eczema and each of the many
other skin AEs (Table 3) attributed to PEG-INF/RBV is still lacking. Yet, one might consider
that notwithstanding the specific clinical and histological characteristics exhibited by each of
the skin unfavorable events observed, many of them show a mixed type III and IV hypersen‐
sitivity reaction pattern in which Th-1 shifted inflammatory clones are likely to drive the
inflammatory process. In such an immunopathogenetic framework, both the well-known
proinflammatory properties of interferon and the multifaceted immune enhancing effects
exerted by ribavirin on Th-1 cell mediated processes [88], may well intervene by worsening
the course of pre-existing conditions, or triggering the new onset of diseases in subjects who
would otherwise be unaffected clinically.
Figure 17. Erythematous patches at the site of injection of INF
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Figure 18. Vague eczematous patches on the extensor aspects of the limbs
Figure 19. Eczema involving areas exposed to friction
Figure 20. A ‘coin’ shaped, sharply demarcated eczematous lesion (nummular eczema)
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Figure 21. Nummular eczema: dyschromic sequelae
Figure 22. Prurigo nodularis - Bottom left corner: closeup of an excoriated nodule
 
(a) (b) (c) 
Figure 23. Clinical grading of eczema: A, acute; B, subacute; C, chronic
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Figure 24. Fixed drug eruption (Courtesy of Doctor R. Pellicano, San Giovanni Rotondo, Italy)
4.2. Skin adverse effects related to newly developed agents for treatment of chronic HCV
infection
‘Telaprevir dermatitis’: what are we dealing with?
The recent introduction of the NS3/4A protease inhibitors telaprevir and boceprevir, the first
direct-acting antiviral agents (DAAs) approved for treatment of chronic infection with
genotype 1 HCV in conjunction with PEG-INF and RBV, has led to increased viral response
rates. Although PEG-INF plus RBV are still responsible for the majority of adverse effects
related to ‘triple therapy’, DAA have been reported to induce exacerbation of traditional
adverse events and development of new undesired occurrences.
As more specifically regards skin unfavorable manifestations, telaprevir seems to play a major
role. Pruritus, independent of, or associated with skin manifestations are in fact the most
significant cutaneous AEs [78, 90]. The analysis of the safety profile exhibited by telaprevir in
the phase 1 to 3 studies available in the literature has yielded the almost invariable finding of
consistently increased frequency rates of skin rashes appearing during telaprevir treatment
phases compared with those occurring under SOC regimens. Rashes of any severity have been
in fact reported in 36 to 82% of patients [90-93], and seemed to be virtually indistinguishable
from the PEG-IFN/RBV-related rashes, having ‘dry skin’, ‘pruritus’ and ‘eczema’ as prominent
features. It has also been noted that some rashes were of greater severity and occurred on a
larger body surface area (BSA), but in the vast majority of cases the BSA 30% limit was not
exceeded. Of note, these rashes have been reported to largely occur during the first weeks of
treatment and recover after telaprevir withdrawal.
Some efforts have recently been made to conceive strategy protocols of early intervention to
minimize treatment-linked AEs. As for skin AEs, in the trials carried out by Jacobson and
coworkers [94] and Zeuzem and coworkers [95] a ‘rash management plan’ was established
and the intensity of rash was accordingly graded as grade 1 (mild, localized to one or several
sites); grade 2 (moderate, with a diffuse skin eruption involving up to 50% of the body surface);
and grade 3 (severe, involving more than 50% of the body surface, or rash with the appearance
of substantial systemic signs or symptoms). In patients with a progressive grade 2 rash, or any
grade 3 rash telaprevir administration was stopped, while continuing PEG-INF/RBV treat‐
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ment. In case of worsening of the rash within the subsequent 7 days, RBV (and possibly PEG-
INF) was to be discontinued as well (Table 4.A) [94, 95].
Severe rashes were observed in only 3-7% of patients, with some cases featuring Stevens-
Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulo‐
sis, or ‘drug rash with eosinophilia and systemic symptoms’ (DRESS) syndromes. As a
whole, however, only in 4-7% of subjects enrolled in clinical trials was telaprevir discon‐
tinued owing to skin rash. The absolute majority of skin rashes were instead mild to mod‐
erate,  and  were  quite  easily  controlled  through  oral  anti-histamines,  topical  emollients
and/or high-to-mean potency steroid ointments [96].
There is a great number of reports concerning prevalence of and clinical warnings raised
by  telaprevir-induced  dermatologic  manifestations.  However,  to  the  best  of  my  knowl‐
edge, no evidence is yet available in the literature giving ‘telaprevir dermatitis’ some taxo‐
nomical profiling at least on morphological grounds. At the time of this writing, those of
Cacoub and coworkers [78], Dupin and coworkers [97], Kumada and coworkers [93] and
Awwad and coworkers [98] are the sole papers in the literature reporting some iconogra‐
phy  of  telaprevir-related  dermatological  AEs.  Skin  lesions  are  almost  invariably  and
vaguely  referred  to  as  ‘primarily  eczematous’  or  ‘maculopapular’,  and,  as  such,  indeed
appear to be rather indiscernible from those allegedly linked to PEG-INF/RBV. No or lit‐
tle information is available on cases that are ‘not eczematous’. Could they be alternative‐
ly  urticarial,  dermographical,  or  polymorphic?  When  the  rash  is  ‘eczematous’,  are  the
skin lesions haphazard or symmetrical? Had any of  these eczematous patients a history
of  delayed-type  hypersensitivity  and/or  was  he  subsequently  skin  tested?  Related  to
these circumstances, one should consider that the clinical grading of skin AEs (as descri‐
bed above),  and thus the possibility of driving decision-making algorithms, currently lie
on the need to assess severity of the skin rash through criteria that are not strict enough
to  prevent  some unpredictable  levels  of  intra-  and inter-observer  variability.  In  this  re‐
spect,  one  may consider  the  rather  significant  differences  existing  in  ‘rash  management
strategies’ conceived by different research groups (see Table 4.A and 4.B for comparison).
Consequently,  extensive  dermatologist-oriented surveys  are  still  warranted to  better  de‐
fine the clinical edges (if any) of ‘telaprevir dermatitis’ and possibly shed new light on the
pathophysiology of such largely unexplained occurrences.
The same insufficiencies observed in morphological assessment of AEs related to telapre‐
vir  also  involve  studies  carried  out  with  other  DAAs,  which  seem however  to  bear  an
overall  lower potential  of  inducing dermatological  unfavorable manifestations compared
to the former.  In this  regard,  in two recent  phase 3  trials  [99,  100]  in which boceprevir
was administered in combination with PEG-INF plus RBV for up to 44 weeks after a 4-
week ‘lead-in’ phase with SOC agents, skin AEs (such as, ‘rash’ and ‘dry skin’) were ob‐
served in consistently  lower rates  of  patients  compared to  telaprevir  studies,  and in no
case were they the reason for pre-term discontinuation of treatment. Interestingly, in the
trial  involving  naïve  subjects  [99],  frequency  of  ‘pruritus’,  ‘rash’  and  ‘dry  skin’  were
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found to  be  not  significantly  different  between SOC and boceprevir  groups.  Instead,  in
the trial  involving non-naïve subjects [100],  ‘rash’ and ‘dry skin’ were reported in up to
17  and  22%  of  patients,  respectively,  and  between-arm  differences  with  respect  to  this
were  found to  be  significant.  Reasons  for  the  above  discordances  appear  definitely  ob‐
scure.
Concerning possible reasons for the striking differences observed between telaprevir and
boceprevir in terms of cutaneous (and noncutaneous) pathogeneticy, the obviously differ‐
ent chemical structures of the two agents may well account for most of intrinsic differen‐
ces  in  specific  harmful  potentials.  However  the  different  treatment  protocols  applied
(telaprevir  associated with SOC agents  at  the  beginning of  the  trial  period,  while  boce‐
previr started only after a lead-in phase of SOC alone) could also be taken into consider‐
ation as  being able  to  influence  type and severity  of  undesired complaints.  Particularly
regarding skin AEs, one might speculate that PEG-INF and RBV, being delivered in asso‐
ciation with telaprevir from the beginning of the trial,  act as ‘proinflammatory boosters’
by virtue of their multifarious immunomodulating actions which would be able to create
a sort of synergy with telaprevir noxious capacity.
As  for  other  developing  DAAs,  the  protease  inhibitor  BI  201335  has  also  to  be  consid‐
ered. A small trial enrolling 53 chronic HCV genotype-1 patients (34 treatment-naïve and
19 treatment-experienced subjects)  evaluated efficacy and safety profiles of ‘multiple ris‐
ing dose’ regimens of BI 201335 in the short-term (4 weeks) [101]. In this study, no skin
AEs during therapy with BI 201335 alone were reported.  ‘Mild rash or photosensitivity’
was observed only in four patients during combined treatment with SOC agents,  but in
no case  did this  cause  pre-term treatment  discontinuation.  It  should additionally  be  re‐
ported that,  according to interim (12 weeks)  outcome analyses of  an earlier  study of  BI
201335 with PegIFN/RBV in 288 patients in the long-term (24 weeks) [102], ‘mostly mild
to  moderate  rash  and  photosensitivity  reactions’  were  referred  to  as  the  most  frequent
adverse  events,  along  with  gastrointestinal  disorders.  ‘Severe  rash’  was  observed  in
0.7-1.3% of  subjects  receiving daily  BI  201335 doses  of  240mg,  while  this  rate  increased
up to 5.7% in patients undergoing daily doses of 480 mg. Finally, in a phase 1b open-la‐
bel  trial,  34  treatment-naïve  patients  with  chronic  HCV-1  infection were  randomized to
receive an association of the polymerase inhibitor BI 207127 (400 to 600 mg 3 times daily)
and  BI  201335  (120  mg  once  daily)  plus  RBV  (1000  to  1200  mg  per  day)  for  4  weeks
[103].  In this  study a ‘rash management plan’  was established and the intensity of  skin
AEs was accordingly graded as mild  (localized), moderate  (diffuse, 30% to 70% body sur‐
face area), or severe (diffuse generalized, mucous membrane involvement, organ dysfunc‐
tion,  signs  of  anaphylaxis,  or  life  threatening).  A  part  from  mild  gastrointestinal
disorders (diarrhea, nausea, vomiting), a mild ‘rash or photosensitivity reaction’ was ob‐
served in 42% of  subjects  receiving the highest  daily dosages.  Yet,  due to drug overlap
within the treatment regimens, it was not possible to ascribe any of these AEs to an indi‐
vidual  compound.  Nevertheless,  no  severe  AEs  were  observed,  and  no  AE-related  pre-
term discontinuation of treatment occurred throughout the study period.
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 Rash severity 
 
 
Description 
 
Early intervention strategy protocol 
 
Grade 1 
 
mild, localized to one or 
several sites 
 
 
 
Stable mild/moderate rash        
Medical management performed at the discretion 
of the investigator  
Grade 2 
 
moderate, with a diffuse skin 
eruption involving up to 50% 
of the body surface 
 
 
Progressive moderate rash, or severe rash 
telaprevir discontinued 
 
 
Rash not improving within 7 days       
RBV ± PEG-INF discontinued (suggested) 
 
 
Grade 3 
 
severe, involving more than 
50% of the body surface, or 
rash with the appearance of 
substantial systemic signs or 
symptoms 
 
 
Table 4.A Telaprevir - Skin AEs severity scale and rash management plan according with Jacobson et al [94] and
Zeuzem et al [95]
 
 
Rash severity 
 
 
Description 
 
Early intervention strategy protocol 
 
Grade 1 
 
Localized skin lesions 
 
 
Routine, non specific management 
 
 
Grade 2 
 
Diffuse or multiple skin lesions
 
 
 
 
 
 
Telaprevir discontinued 
PEG-IFN and RBV reduced or discontinued, 
as required 
Dermatologists’ consultation for diagnosis and 
specific cares 
 
 
Grade 3 
 
Skin lesions covering >50% of 
the body surface or rashes with 
some characteristics such as 
bullae, ulceration of mucous 
membrane,  epidermal 
detachment detachment, target 
lesion or significant systemic 
signs 
 
 
Grade 4 
 
Stevens–Johnson syndrome 
and drug rashes with 
eosinophilia and systemic          
symptoms (DRESS) 
 
 
Table 4.B Telaprevir - Skin AEs severity scale and rash management plan according with Kumada et al [93]
4.3. Skin adverse effects related to treatment of HBV infection
Current mainstays of treatment for HBV infection are interferon (INF) and nucleotide/
nucleoside analogues (NAs), which are used following standardized guidelines in both ‘first
line, definite duration’ and ‘long-term, indefinite duration’ protocols [104]. Considering, on
one hand, the high diffusion of HBV infection in the general population [105] and the signifi‐
cant amounts of these agents that must have been, and are delivered worldwide accordingly,
and on the other hand, the vast arrays of skin unfavorable manifestations observed under
treatment for HCV infection (see above paragraph), the substantial paucity in the literature of
systematic reviews or clinical reports on cutaneous side effects occurring in association with
HBV treatment is somewhat surprising. The difference will be evident at a glance by comparing
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Table 3 and 5. One may confidently infer that NAs are overall biologically inert within the
‘skin milieu’, but interferon does remain a shared weapon in the treatment of both viral agents,
and has been the backbone tool in the management of HBV infection for many years before
the advent of NAs. Differences in the prevalence rates of HBV and HCV infection worldwide,
or mere underreporting could be well invoked in this respect. Yet, a possible explanation of
such striking divergence between INF impact on the skin of patients with HBV and HCV
infection could also lie in the more faithful hepatotropism of HBV compared to HCV. The latter
has indeed been found in many tissue other than liver [106, 107], skin included [108, 109]. These
circumstances might suggest a possible (yet indeterminable) synergy in skin pathogenicity
between INF and HCV, which could play some direct role in local promotion of INF-related
skin untoward manifestations in HCV but not in HBV patients. Another explanatory hypoth‐
esis could lie on the unique capacity of HCV (not ascribed to HBV) to induce B cell lympho‐
proliferation and trigger a number of autoimmune processes.
4.3.1. Skin events related to INF
Apart from the almost invariable occurrence of an erythematous roundish plaque at the
injection site (Figure 17), administration of INF in HBV patients has been implicated in the
following undesired effects (Table 5): skin necrosis at the injection site [110], angioedema-
urticaria syndrome [111], diffuse patchy erythematous rash [112], morbilliform exanthema
[113], psoriasis [114, 115], vitiligo [115], lichen planus [116], ocular trichomegaly [117].
4.3.2. Skin events related to NAs
The potential exhibited by these agents to sustain any skin pathogenicity appears to be overall
contained. Not better specified ‘rash and/or anaphylaxis’ have been recently assumed to be
‘infrequent’ [1/103 to 1/104: tenofovir), ‘common’ [1/10 to 1/102: lamivudine, telbivudine and
adefovir) or ‘with unknown frequency’ (entecavir) [104]. Reports on NAs-related skin
untoward effects are quite scanty in the literature. Lamivudine has been reported in relation
with an ichthyosiform eruption in a patient with chronic HBV infection [118]. Clinical and
histological iconography is also available of a severe, diffuse eczematous rash observed in an
additional case of HBV infection in a Korean-language paper [119]. Reports of other skin AEs
related to lamivudine refer to subject with HIV infection [120]. Entecavir has been reported to
cause a diffuse maculopapular rash in one HBV patient [121] and an ‘immediate allergy’
erythematous eruption in an additional HBV patient [122]. Tenofovir has been implicated in
development of a maculopapular rash on the face, extremities and trunk observed in HIV
patients [123]. Adefovir has been found to trigger a case of Stevens-Johnson/toxic epidermal
necrolysis overlap syndrome in a patient with HBV infection [124].
5. Virus-related liver hazards related to treatment of skin diseases
Treatment of a wide variety of skin inflammatory, immune mediated disorders poses a
concrete risk for hepatic disease and toxicity. Possible undesired liver injuries are constantly
a significant limitation in case management with a great number of pharmaceutical agents.
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Hepatotoxicity can derive directly from many drugs used in the treatment of psoriasis, such
as methotrexate, ciclosporin or retinoids. Potential hazards may also indirectly result from
drugs used to contrast unfavorable complications of dermatological treatment regimens, such
as reactivated tuberculosis necessitating isoniazid or rifampicin administration. Also, unsur‐
veyed administration of immunomodulating/immunosuppressive agents, ranging from
corticosteroids to TNF- α antagonists, may be also associated with exacerbation of an under‐
lying chronic viral hepatitis [125-127].
An in-depth analysis of all skin disorders the treatment of which may result in liver injury is
certainly beyond the scope of this chapter. Instead, I will only concisely focus on systemic
therapy of moderate-to-severe psoriasis (Table 6), in view of the fact that psoriasis is the leading
item in cutaneous immune mediated pathology affecting 1 to 3% of population in Western
industrialized countries [128]. Notably, it has been estimated that more than 11 million people
suffer from psoriasis in Europe [129, 130]. Severity of psoriasis is ‘quantitatively’ assessed
through so-called ‘psoriasis area-and-severity index’ (PASI), whose score ranges from 0 to 72
Injection site (local) reactions
-ill-defined, roundish, pruritic, self-recovering erythematous patches (figure 17)
-skin necrosis
Non local, or generalized reactions
-angioedema-urticaria syndrome
-diffuse patchy erythematous rash
-morbilliform exanthema
-psoriasis
-vitiligo
-lichen planus
-ocular trichomegaly
A – related to INF
Lamivudine:
-ichthyosiform eruption
-severe, diffuse eczematous rash
Entecavir:
-diffuse maculopapular rash
-erythematous eruption
Adefovir:
-Stevens-Johnson/toxic epidermal necrolysis overlap syndrome
B – related to NAs
Table 5. Skin adverse effects under treatment of HBV infection
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(with higher scores indicating more severe disease). Overall, patients with PASI scores of 12
or higher are candidates to systemic treatment. Yet, the magnitude of disease severity is also
to be evaluated ‘qualitatively’, considering that the skin condition may often lead to substantial
burden in terms of disability and psychosocial stigmatization (I believe that the reader will
readily agree on this view after taking a look at figures 25.A to -D). In this regard, it has been
calculated that impairment of physical and mental functioning in psoriatic patients is not
consistently different from that observed in subjects with major medical illnesses, such as
cancer, heart disease, chronic respiratory disease or type 2 diabetes [131]. Also, it should be
underlined that a striking discrepancy between the objective ‘weight’ of the disease on clinical
ground and the patients’ subjective appraisal of the skin problem ‘dimension’ often exists
[132]. The degree of patient dissatisfaction with treatment outcome is frequently high, and
significant levels of intentional noncompliance with prescribed regimens are not uncommon
accordingly [133].
Huge numbers of patients with psoriasis undergo systemic treatment, and thus are subject to
some risk of undesired liver injury. In this context, the possibility of reactivation of chronic
hepatitis B and C is of significant concern. As for Europe, the recently audited ‘European S3-
Guidelines on the systemic treatment of psoriasis vulgaris’ [134] reflect a high level of physician
awareness about this risk. ‘Active chronic hepatitis B’ and ‘hepatitis C’, respectively, are listed
as absolute and relative contraindications on use of many systemic treatments. Accordingly,
pre-treatment necessary measures include HBV/HCV serology and liver function tests. Liver
enzymes are also to be evaluated throughout the treatment period at regular intervals.
Moreover, some caveats concerning the use of anti-TNFα biologic agents (such as infliximab,
etanercept, alefacept, efalizumab) in chronic carriers of HBV and HCV have been explicitly
expressed [134]. Pre-treatment or concomitant use of antiviral agents has been assumed to
allow systemic treatment use in some trials involving non-dermatological (Crohn’s disease)
patients, with no reports of viral reactivation under high potency regimens [135]. Co-admin‐
istration of lamivudine has also been considered in the management of HBsAg carrier psoriatic
patients [136, 137]. However, concerns are raised by the recognized risk of viral resistance
development and acute disease flare occurrence after prolonged use of lamivudine. Thus, more
studies are warranted to reliably assess whether antiviral prophylaxis is a viable option in the
management of chronic inflammatory conditions.
5.1. Safety profile of traditional (‘nonbiologic’) and anti-TNFα (‘biologic’) agents in viral
hepatitis patients
First, it must be strongly emphasized that reliable assessment of the safety profile of systemic
agents employed in the treatment of moderate-to-severe psoriasis is inherently biased by many
factors. Available information from randomized trials is often poor owing to low sample size
and insufficient power to ascertain safety outcome conclusively [138]. Furthermore, clinical
trials typically involve healthy patients or, at least, not ‘difficult-to-treat’ cases. In this regard,
an inadequate representation in case populations of subjects with some relevant covariates,
such as pediatric or elderly age, pregnancy or breastfeeding, history of kidney or liver disease,
cancer, HIV, HBV and HCV infection, has been consistently documented [139-141]. Taken as
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a whole, these circumstances dictate extreme caution in extrapolating results to the broader
population of patients in day-to-day clinical practice.
5.1.1. HBV setting
Many papers can be found in the literature reporting TNFα inhibitors to worsen chronic HBV
disease in subjects suffering from noncutaneous diseases, such as rheumatic conditions or
Crohn’s disease [142-144]. Instead, I found only one case concerning a patient with psoriasis
vulgaris and psoriatic arthropathy caused by adalimumab [126]. An additional case, related
to infliximab, was reported in the results of a questionnaire-based survey involving a nation‐
wide sample of physician members of the American Academy of Dermatology in 2011 [145].
As for nonbiologic treatment-related events, a retrospective study carried out on ninety-eight
patients undergoing prolonged corticosteroid treatment for psoriasis-unrelated skin condi‐
tions (namely, pemphigus vulgaris and dermatomyositis) showed only four cases of HBV
reactivation, two of whom had a fatal outcome [125].
Reasons for such low reporting rates remain to be fully clarified. A role of so-called ‘Weber
effect’ [146], or other factors possibly affecting spontaneous reporting of adverse events, might
be invoked. Alternatively, a consistently high level of alertness among dermatologists might
be assumed. In this respect, it can incidentally be considered that since 2005 all Italian derma‐
tologists involved in the management of psoriasis with ‘biologic’ and ‘nonbiologic’ systemic
agents have to mandatorily adhere to the well-established pharmacovigilance roadmap dictated
by the so-called ‘Psocare’ program.1 Moreover, another independent aim-oriented dermatolo‐
gy registry network, the Psonet (http://www.psonet.eu) [129, 147], has more recently branched
off from the Psocare program in order to merge data and strategy protocols from most European
countries, along with Israel and Australia. Properly surveyed administration of anti-TNFα
agents in HBV patients has been reported to be an overall safe treatment option in the setting
of both noncutaneous inflammatory conditions [148, 149] as well as psoriasis [136, 150, 151].
However, the use of systemic (‘biologic’ or ‘nonbiologic’) agents in psoriatic patients who are
chronic carriers of HBV is only an end-line tool in the ranking of therapeutic options, photother‐
apy and/or topical agents being more properly recommended (Table 7) [139].
5.1.2. HCV setting
Despite the wide range of noncutaneous inflammatory diseases in which TNFα inhibitors are
now used as well-established therapeutic tools, literature yields only few papers in which these
1 Psocare is an Italian joint venture of psoriasis patients, dermatologists, epidemiologists and drug safety experts who are
proactively involved since 2005 in a nationwide process linking drug prescription data to information on treatment outcome,
such as effectiveness and long-term safety. Registration and participation to Psocare program, which is funded by the
Italian Drug Administration Agency (AIFA), is mandatory to administer conventional treatments (including photothera‐
py) and new generation biologics. To date, Italian regional health authorities have appointed nearly 150 reference centers,
in which patients’ admission and follow-up visits are carried out, and demographic and lifestyle characteristics, disease
severity, treatment exposure, treatment outcome, and any medical event (i.e. new diagnoses, hospitalizations, outpa‐
tient specialist visits) are registered. Before starting therapy, and throughout the treatment period, patients are rigidly
evaluated according to standardized guidelines aimed at assuring the closest postmarketing surveillance of effective‐
ness and safety of systemic agents.
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agents are reported to worsen HCV disease in subjects suffering from sole rheumatoid arthritis
[141, 152-156]. TNFα inhibitors have also been assayed in HCV patients suffering from
psoriasis. In this context, a number of small case series or anecdotal cases have been reported
in which etanercept, efalizumab and alefacept do not induced HCV exacerbation. Of note, mild
improvement in viral load and/or liver function tests were also observed in many of these cases
[151, 157-170]. Only in one case, described by Ventura and coworkers [163], a significant
increase of viral load (from 1.52×104 to 1.94×106 IU/mL), not coupled with increased liver
enzymes, was observed after a 6-month therapy and led to treatment discontinuation. On the
basis of such evidence, the overall harmful impact of anti-TNFα therapies in the setting of
chronic HCV infection may appear to be lower than that exhibited in HBV infection. Indeed,
the TNFα cascade has been consistently involved in the pathogenesis of liver damage, scar
formation and fibrosis in chronic hepatitis C, and promising data have been reported sug‐
gesting a protective role of TNFα inhibitors against both INF-RBV-related undesired effects
and virus-related hepatocyte injury [171]. Nevertheless, treatment of HCV infected psoriasis
populations is subject to the same caution expressed by current guidelines for the management
of patients who are chronic carriers of HBV [134]. Concerning this aspect, two different
authority panels have recently audited all pros and cons, and drawn up a ranking list each of
therapeutic options for treatment of moderate-to-severe psoriasis in HCV patients (Tables 8.A
and B) [139, 172].
As for traditional ‘nonbiologic’ therapy, to the best of my knowledge, literature remains
substantially silent with regard to acute flares of hepatitis deriving from treatment of psoriasis
or other skin inflammatory conditions. I was able to find just one case of HCV reactivation
occurring in a psoriatic patient after reduction of daily ciclosporin dosage [127]. By contrast,
many cases of HCV reactivation have been reported during tapering of ciclosporin regimens
in noncutaneous disease settings, such as bone marrow transplanted subjects [173]. In my
opinion, reasons for possible underreporting in the dermatological literature of any drug-
related liver undesired effects in the HCV setting are very likely to be the same as those
discussed in paragraph 4.1.1.
As shown in Table 6, the management of moderate-to-severe psoriasis lies in a wide panel of
agents which may often be a double-edged weapon owing to their broad immunosuppressive
action. This concern is prompting continuous efforts to develop pharmacological agents (such
as the new anti-interleukin-17 antibodies) [174-176] which are able to interfere with the
TNFα cascade as downstream as possible, and are thus more likely to significantly lower the
risk for side-effects related to impaired immune surveillance. Nevertheless, in more or less
recent years (i.e., well after the breakthrough of ‘TNFα inhibitor era’) some faint interest has
been renewed for traditional psoriasis treatment modalities, eg so-called Goeckerman treat‐
ment [177] or oral ciclosporin [178, 179]. In my view, the debate ‘biologics versus nonbiologics’
for management of skin inflammatory conditions is on the whole still highly controversial,
and the decision-making process in daily clinical practice seems to be more conveniently left
to the physician’s wisdom.
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Figure 25. Psoriasis
-Methotrexate -Alefacept
-Thioguanine -Efalizumab
-Ciclosporin -Ustekinumab
-Retinoids -Ixekizumab
-Fumaric acid esters -brodalumab
-Adalimumab -secukinumab
-Etanercept -tofacitinib
-Infliximab
Table 6. Systemic therapy for psoriasis
Rank Therapeutic option
1 UV-B narrowband
2 UV-B broadband
3 Topical corticosteroids
4 UV plus topical anthralin, or crude coal tar (*)
5 Topical steroids and calcipotriene
6 UV-A plus psoralen (P-UV-A)
7 UV plus acitretin
8 Efalizumab
9 Acitretin
UV = ultraviolet phototherapy; (*) Goeckerman treatment [177]
Table 7. Ranking of therapeutic options for treatment of moderate-to-severe psoriasis in chronic carriers of HBV.
From: Strober et al [139], modified
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Rank Therapeutic option
1 Etanercept
2 UVB narrowband
3 TNF-inhibitor (without concern for any individual drug)
4 Adalimumab
5 UVB broadband
6 Infliximab
7 Topical corticosteroid in combination with calcipotriene
8 Topical corticosteroids
9 Efalizumab
10 Alefacept
A: From: Strober et al [139], modified
Rank Therapeutic option
First line UVB narrowband
UVB broadband
Topical therapies
Second line Acitretin
Etanercept
Infliximab
Adalimumab
PUVA
Third line Alefacept
Cyclosporine
Efalizumab
Azathioprine
B: From: Frankel et al [180], modified
Table 8. Ranking of therapeutic options for treatment of moderate-to-severe psoriasis in chronic carriers of HCV
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